NCT03558880

Brief Summary

In breast reduction surgery, pain control is usually performed with tumescent anesthesia, thoracic epidural anesthesia, intercostal nerve blocks and paravertebral block applications. Tumescent anesthesia is also preferred by plastic surgeons because of the varying risk of thoracic epidural anesthesia and paravertebral block applications. After the Erector spinae block was first described by Forero in 2016, it was reported to have been applied in many cases, including breast surgery. It is considered to be a safer block because of the presence of paravertebral block-like activity and the location where the needle is guided away from the pleura. The investigators aimed to compare postoperative analgesia consumption, pain scores and patient satisfaction of erector spine block with tumescent anesthesia in patients who underwent reduction mammoplasty operation under general anesthesia in this double-blind prospective randomized study.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
44

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jul 2017

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2017

Completed
11 months until next milestone

First Submitted

Initial submission to the registry

June 5, 2018

Completed
10 days until next milestone

First Posted

Study publicly available on registry

June 15, 2018

Completed
16 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2018

Completed
29 days until next milestone

Study Completion

Last participant's last visit for all outcomes

July 30, 2018

Completed
Last Updated

August 1, 2018

Status Verified

June 1, 2018

Enrollment Period

1 year

First QC Date

June 5, 2018

Last Update Submit

July 31, 2018

Conditions

Outcome Measures

Primary Outcomes (1)

  • Use of analgesic consumptions

    Total tramadol consumptions with patient controlled device

    24 hour

Secondary Outcomes (1)

  • Numeric Pain Rating Scale

    30 minute, 1,2,4,6,12,24 hour

Study Arms (2)

Erector Spinae Plane Block

ACTIVE COMPARATOR

Before the general anesthesia Erector Spinae Plane Block was performed.

Procedure: Erector Spinae Plane Block

Tumescent Anesthesia

ACTIVE COMPARATOR

After the general anesthesia was given, 1 mL of 0.1% adrenaline (1/1000) and as 20 mL of 0.5% bupivacaine solution of tumescent in a total of 1000 mL Ringer's lactate applied by the surgeon applied equally to both breasts

Procedure: Tumescent Anesthesia

Interventions

Erector Spinae Plane Block was performed

Erector Spinae Plane Block

Tumescent Anesthesia was applied

Tumescent Anesthesia

Eligibility Criteria

Age18 Years - 65 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • The American Society of Anesthesiologists physical status classification I-III undergoing reduction mammoplasty

You may not qualify if:

  • History of allergic reactions to local anesthetics Rash or infection at the injection site Anatomical abnormality Bleeding diatheses Coagulopathy liver diseases

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Kahramanmaras Sutcu Imam University Hospital

Kahramanmaraş, Turkey (Türkiye)

Location

Related Publications (1)

  • Forero M, Adhikary SD, Lopez H, Tsui C, Chin KJ. The Erector Spinae Plane Block: A Novel Analgesic Technique in Thoracic Neuropathic Pain. Reg Anesth Pain Med. 2016 Sep-Oct;41(5):621-7. doi: 10.1097/AAP.0000000000000451.

    PMID: 27501016BACKGROUND

MeSH Terms

Conditions

GigantomastiaPain, Postoperative

Condition Hierarchy (Ancestors)

Postoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsPainNeurologic ManifestationsSigns and Symptoms

Study Officials

  • Gözen Öksüz, M.D.

    Kahramanmaras Sutcu Imam University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

June 5, 2018

First Posted

June 15, 2018

Study Start

July 1, 2017

Primary Completion

July 1, 2018

Study Completion

July 30, 2018

Last Updated

August 1, 2018

Record last verified: 2018-06

Data Sharing

IPD Sharing
Will not share

Locations